IMMP

Immutep Limited

3.14 USD
+0.02 (+0.64%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immutep Limited stock is up 25.1% since 30 days ago. The next earnings date is Jun 4, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 69.23% of the previous 12 May’s closed higher than April. 100% of analysts rate it a buy.

About Immutep Limited

Immutep Limited engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer.